Phase 3 Obesity Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who were male or female at birth
- People who are 18 years of age or older at the time of signing the consent form
- People who have been diagnosed with knee osteoarthritis based on recognised medical criteria, with visible changes on X-ray showing moderate-level joint damage (graded 2 or 3 on a standard scale) in the knee being studied — this is usually the more painful knee, or the dominant leg if both knees hurt equally
- People whose knee pain in the target knee first appeared more than 90 days before the screening visit, and who have experienced pain on more than 15 days out of the past 30 days
- People who are willing to stop taking most pain relief medicines for 72 hours before certain study visits (a limited amount of paracetamol — up to 4 grams per day — is allowed as a backup, but must be stopped at least 24 hours before those visits)
Who may not be able to join:
- People whose blood sugar control measure (HbA1c) is 6.5% or higher, based on a blood test taken at the screening visit
- People who have a history of type 1 or type 2 diabetes, either as reported by themselves or recorded in their medical records
- People who have previously been treated with a class of medicines that includes GLP-1 receptor agonists, dual GLP-1/GIP medicines, or amylin analogues (these are certain types of medicines sometimes used for blood sugar or weight management) (confirm with trial site)
- People who have an artificial joint or have had a joint replacement in the knee being studied
- People who have had a procedure inside the target knee joint (arthroscopy) or an injection into the target knee within the past 90 days before screening
- People who have any other joint condition affecting the target knee, including gout or pseudogout
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Clinical Transparency (dept. 2834), Novo Nordisk A/S
Phone: (+1) 866-867-7178
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
5 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Relative change in body weight; Change in WOMAC Osteoarthritis Index NRS 3.1 (24-hour) (WOMAC) pain score
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.